Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 9, 2011, Pages 1254-1261

  Zhang, Ming ^a,b   Li, Si Yang ^a   Rosenthal, Ian M ^a   Almeida, Deepak V ^a   Ahmad, Zahoor ^a,c   Converse, Paul J ^a   Peloquin, Charles A ^d   Nuermberger, Eric L ^a   Grosset, Jacques H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EPFL   (Switzerland)

^c CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Drug resistance; Immune deficient mice; Rifampin; Rifapentine; Tuberculosis

Indexed keywords

CORTISONE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BAGG ALBINO MOUSE; CLINICAL ASSESSMENT; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNE DEFICIENCY; LUNG HOMOGENATE; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RELAPSE; TISSUE CULTURE; TREATMENT DURATION; TUBERCULOSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; CORTISONE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; ISONIAZID; LUNG; MICE; MICE, INBRED BALB C; MICE, NUDE; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RECURRENCE; RIFAMPIN; TIME FACTORS; TUBERCULOSIS, PULMONARY;

EID: 79955502537     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201012-1949OC     Document Type: Article

References (40)

1. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
2. McCune RM, Feldmann FM, Lambert HP, McDermott W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 1966;123:445-468.
3. McCune RM, Feldmann FM, McDermott W. Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli. J Exp Med 1966; 123:469-486.
4. McCune RM Jr, McDermott W, Tompsett R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 1956;104:763-802.
5. McCune RM Jr, Tompsett R. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med 1956;104:737-762.
6. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 1978;53:5-12. (Pubitemid 9243249)
7. Grumbach F. La durée optimale de l'antibiothérapie par l'association isoniazide 1 rifampicine dans la tuberculose expérimentale de la souris. Etude de la phase post-thérapeutique. Epreuve de la cortisone. Rev Fr Mal Respir 1975;3:625-634.
8. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-1021. (Pubitemid 36548927)
9. Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell PC, Daley CL. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007;175:1199-1206. (Pubitemid 46855463)
10. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, Mugerwa RD, Ellner JJ. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997;337:801-808. (Pubitemid 27391629)
11. Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med 2008;178:989-993.
12. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007;4:e344.
13. Grosset J, Zhang M. Sterilization of tuberculosis (TB) infection in immune-deficient mice treated with rifapentine (P), isoniazid (H) and pyrazinamide (Z). Am J Respir Crit Care Med 2010;181:A5449.
14. Zhang M, Li SY, Rosenthal IM, Peloquin CA, Nuermberger EL, Grosset J. Failure of daily treatment for tuberculosis (TB) with rifampin (R), isoniazid (H), and pyrazinamide (Z) in immunedeficient mice. Am J Respir Crit Care Med 2010;181:A5448.
15. Ioerger TR, Feng Y, Ganesula K, Chen X, Dobos KM, Fortune S, Jacobs WR Jr, Mizrahi V, Parish T, Rubin E, et al. Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J Bacteriol 2010;192:3645-3653.
16. Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 2009;53:4178-4184.
17. Grosset J, Ji B. Experimental chemotherapy of mycobacterial diseases. In: Gangadharam PRJ, Jenkins PA, editors. Mycobacteria. II. Chemotherapy. New York: Chapman & Hall; 1988. pp. 51-97.
18. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, Rist N, Smelev NA. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969;41:21-43.
19. Grosset J, Truffot-Pernot C, Cambau E. Bacteriology of tuberculosis. In: Reichman LB, Hershfield ES, editors. Tuberculosis: a comprehensive international approach. New York: Marcel Dekker; 2000. pp. 157-185.
20. Woods GL, Warren NG, Inderlied CB. Susceptibility test methods: mycobacteria, Nocardia, and other actinomycetes. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of clinical microbiology, 9th ed. Washington: ASM Press; 2007. pp. 1223-1247.
21. Espinal M. What is the "fall and rise" phenomenon and the "sequential regimen" mechanism? In: Frieden T, editor. Toman's tuberculosis, 2nd ed. Geneva: WHO; 2004. pp. 200-202.
22. Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, Lahart C, Weis S, King B, Mangura B, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006;173:350-356. (Pubitemid 43209091)
23. Ridzon R, Whitney CG, McKenna MT, Taylor JP, Ashkar SH, Nitta AT, Harvey SM, Valway S, Woodley C, Cooksey R, et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med 1998;157:1881-1884.
24. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999;353:1843-1847. (Pubitemid 29251017)
25. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005;40:1481-1491. (Pubitemid 40628637)
26. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, Weis S, King B, Shah N, Hodge T, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003;167:1341-1347. (Pubitemid 36609717)
27. Dickinson JM, Ellard GA, Mitchison DA. Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis. Tubercle 1968;49:351-366.
28. Awaness AM, Mitchison DA. Cumulative effects of pulsed exposures of Mycobacterium tuberculosis to isoniazid. Tubercle 1973;54:153-158.
29. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998;2:10-15. (Pubitemid 28108937)
30. Dickinson JM, Mitchison DA. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 1987;68:113-118.
31. Zhang Y, Vilchèze C, Jacobs WR Jr. Mechanisms of drug resistance in Mycobacterium tuberculosis. In: Cole ST, Eisenach KD, McMurray DN, Jacobs WR, Jr., editors. Tuberculosis and the tubercle bacillus. Washington: ASM Press; 2005. pp. 115-140.
32. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998;79:3-29.
33. Converse PJ, Eisenach KD, Theus SA, Nuermberger EL, Tyagi S, Ly LH, Geiman DE, Guo H, Nolan ST, Akar NC, et al. The impact of mouse passaging of Mycobacterium tuberculosis strains prior to virulence testing in the mouse and guinea pig aerosol models. PLoS ONE 2010;5:e10289.
34. Hillemann D, Kubica T, Agzamova R, Venera B, Rusch-Gerdes S, Niemann S. Rifampicin and isoniazid resistance mutations in Mycobacterium tuberculosis strains isolated from patients in Kazakhstan. Int J Tuberc Lung Dis 2005;9:1161-1167. (Pubitemid 41433807)
35. Mokrousov I, Narvskaya O, Otten T, Limeschenko E, Steklova L, Vyshnevskiy B. High prevalence of katG ser315thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother 2002;46:1417-1424.
36. Grosset J. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother 2003;47: 833-836. (Pubitemid 36254203)
37. Grumbach F. Études chimiothérapiques sur la tuberculose avancée de la souris. Adv Tuberc Res 1965;14:31-96.
38. Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004;170:1124-1130. (Pubitemid 39488627)
39. Vernon AA, Iademarco MF. In the treatment of tuberculosis, you get what you pay for. Am J Respir Crit Care Med 2004;170:1040-1042.
40. Fox W. Ambulatory chemotherapy in a developing country: clinical and epidemiological studies. Adv Tuberc Res 1963;12:28-149.